NervGen Pharma is a publicly listed company tracked for investment-relevant business developments.
NervGen's peptide NVG-291 combines a cell-penetrating sequence with a ligand-blocking domain that inhibits the receptor interaction preventing nerve repair, potentially creating an 'Ozempic for the nervous system' platform given the nervous system's foundational importance parallel to the immune system.